The Case for Microgravity Biomanufacturing

The pharmaceutical industry has spent decades optimizing biomanufacturing on Earth. Fermenters, bioreactors, and downstream processing have all been refined to yield better proteins, more consistent cell cultures, and higher throughput. Yet a fundamental constraint has always been present: gravity.

What Gravity Does to Cells

On Earth, gravity introduces sedimentation, convective mixing, and hydrostatic pressure gradients into any biological culture. These forces are invisible to most researchers — they're simply the background conditions of life. But remove them, and cells behave in surprising ways.

In microgravity, cells:

• Form true 3D aggregates rather than settling to the bottom of a vessel
• Express different gene programs, particularly those related to stress response and differentiation
• Produce proteins with altered glycosylation patterns, which can affect drug efficacy and immunogenicity

For some applications, these changes are undesirable. For others, they open entirely new manufacturing possibilities.

The Opportunity

Proteins that are difficult or impossible to crystallize on Earth can form high-quality crystals in microgravity. This has profound implications for structural biology and drug design. More crystalline protein structures mean better drug targets, more precise binding data, and ultimately better medicines.

Beyond crystallization, microgravity enables the culture of tissue constructs that better mimic in vivo physiology. Without gravity flattening cells against a substrate, engineered tissues can develop in ways that more closely resemble how organs actually function.

Why Now?

Three things have converged to make orbital biomanufacturing commercially viable:

1. Launch costs have collapsed. The price per kilogram to low Earth orbit has dropped by an order of magnitude over the past decade.
2. Microgravity research platforms are maturing. From ISS commercial labs to upcoming free-flying stations, dedicated manufacturing platforms are coming online.
3. Biologics are increasingly valuable. The drugs worth the most — monoclonal antibodies, gene therapies, cell therapies — are precisely the products most likely to benefit from microgravity processing.

What Gravitate Bio Is Building

We're developing the infrastructure and processes to make microgravity biomanufacturing practical at commercial scale. That means not just flying experiments, but building repeatable, validated manufacturing workflows that can produce therapeutic quantities of high-value biologics off-planet.

This is early-stage work. The science is real, the commercial case is building, and we're looking for researchers, partners, and investors who see the same opportunity we do.

If that's you — join our waitlist and let's talk.